ProfileGDS5678 / 1418206_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 78% 76% 78% 79% 80% 79% 78% 77% 79% 82% 80% 80% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.367778
GSM967853U87-EV human glioblastoma xenograft - Control 25.4198978
GSM967854U87-EV human glioblastoma xenograft - Control 35.1572476
GSM967855U87-EV human glioblastoma xenograft - Control 45.4911778
GSM967856U87-EV human glioblastoma xenograft - Control 55.5125979
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4503180
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.38779
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.309678
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.2186377
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5340779
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9137382
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7422180
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6589480
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3423878